Enforcement Report - Week of December 7, 2022
Avet Pharmaceuticals Inc., a rapid growth specialty pharmaceutical company focused on the development and distribution of generic medicines in the...
EAST BRUNSWICK, N.J., April 7, 2022 /PRNewswire/ -- Avet Pharmaceuticals Inc. announced today the U.S. launch of its Propofol Injectable Emulsion, USP 10 mg/mL, in 20, 50 and 100 ml Single Patient-Use Vials, an AB rated generic equivalent of DIPRIVAN® (propofol) Injectable Emulsion USP, following its abbreviated new drug application approval from the Food and Drug Administration (FDA). The Company will commence distribution immediately.
Avet Lifescience's Generic Isoproterenol Hydrochloride Receives Approval in the US
Enforcement Report - Week of May 12, 2021
Enforcement Report - Week of December 2, 2020
Heritage Pharma’s Generic Acyclovir Receives Approval In US